Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for Covid-19 or Multisystem Inflammatory Syndrome
JAMA Neurol 78:536-547, LaRovere, K.L.,et al, 2021
Neurologic Complications of Coronavirus Infections
Neurol 94:809-810, Nath, A., 2020
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Neuroimaging Findings of Zika Virus-Associated Neurologic Complications in Adults
AJNR 39:1967-1974, Hygino da Cruz, L.C.,et al, 2018
Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virus-Associated Guillain-Barre Syndrome
JAMA Neurol 74:26-33, Stevens, O.,et al, 2017
Guillain-Barre Syndrome following tuberculosis: A rare association
J Neurosci Rural Pract 8:296-299, Lakhotia, A.N.,et al, 2017
Mycoplasma Pneumoniae Triggering the Guillain-Barre Syndrome
Ann Neurol 80:566-580, Meyer Sauteur, P.M.,et al, 2016
Mechanisms, Causes, and Effects of Hypercapnia
UptoDate Dec, Feller-Kopman, D.J. & Schwartzstein, R.M., 2016
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Neurologic Complications in Dengue Virus Infection
Neurol 83:1601-1609,1590, Sahu, R.,et al, 2014
The Acquired Metabolic Disorders of the Nervous System, Ischemic-Hypoxic Encephalopathy
Adams & Victors Principles of Neurology Chp 40, pg 1133, Ropper, A.H.,et al, 2014
Association between Guillain-Barr� Syndrome and Influenza a (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis
Lancet 381:1461-1468, Salmon, D.,et al, 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Guillain-Barre syndrome associated with pulmonary tuberculosis
BMJ Case Reports DOI:10.1136/bcr-01-2012-5484, Taha, A.A. & Tee, K.H.A., 2012
Recognizing Guillain-Barr� Syndrome in Preschool Children
Neurol 76:807-810, Roodbol,J.,et al, 2011
Should I Have an H1N1 Flu Vaccination After Guillain-Barr�
BMJ 339:635, Price,L., 2009
Guillain-Barr\� Syndrome: Incidence and Mortality Rates in US Hospitals
Neurol 70:16081-1613, Alshekhlee,A.,et al, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004
JAMA 294:2744-2750, Sejvar,J.J.,et al, 2005
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
JAMA 294:2720-2725, Izurieta,H.S.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Guillain-Barre Syndrome Seen in Users of Isotretinoin
BMJ 328:1537, Pritchard,J.,et al, 2004
Guillain-Barre Syndrome Follwoing Influenza Vaccination
JAMA 292:2478-2481, Haber,P.,et al, 2004
Influenza Vaccine and the Risk of Relapse of Guillain-Barre Syndrome
Neurol 55:452-453, Wijdicks,E.F.M. et al, 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Guillain-Barre Syndrome
Lancet 352:635-641, Hahn,A.F., 1998
Acute Inflammatory Demyelinating Polyradiculopathy in Children:Clinical and Electrodiagnostic Studies
Ann Neurol 44:350-356, Delanoe,C.,et al, 1998
The Guillain-Barre Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines
NEJM 339:1797-1802,1845, Lasky,T.,et al, 1998
Measles Vaccination and Guillain-Barre Syndrome
349:14-16, daSilveira,C.M.,et al, 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
An Acute Neurologic Syndrome Temporally Associated with Postexposure Trtm of Rabies
Pediatrics 100:720-721, Mortiere,M.D.&Falcone,A.L., 1997
Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Epidemiology of Guillain-Barre Syndrome in Children:Relationship of Oral Polio Vaccine Administration to Occurrence
J Pediatr 124:220-223, Rantala,H.,et al, 1994
Relapse in Guillain-Barre Syndrome after Treatment with Human Immune Globulin
Neurol 43:872-875, 8571993., Inrani,D.N.,et al, 1993
Human Immune Globulin Infusion in Guillain-Barre Syndrome:Worsening During & After Treatment
Neurol 43:1034-1036, 8571993., Castro,L.H.M.&Ropper,A.H., 1993
Guillain-Barre Syndrome after Exogenous Gangliosides in Italy
BMJ 307:1463-1464, Landi,G.,et al, 1993
GM-1 Ganglioside for Spinal-Cord Injury
NEJM 326:493, Schonhofer,P.S., 1992
Bovine Gangliosides and Acute Motor Polyneuropathy
BMJ 305:1330-1331, Figueras,A.,et al, 1992
Clinical Signs in Severe Guillain-Barre Syndrome: Analysis of 63 Patients
J Neurol Sci 104:143-150, De Jager, A.E.J.,et al, 1991
Guillain-Barre Syndrome After Streptokinase Therapy
Acta Neurologica Scand 82:153, Roquer,J.,et al, 1990